After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharmaceuticals Industries Ltd on Thursday, April 10 said the US Court of Appeals for the Federal Circuit has ruled in ...

Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the ...

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

The injunction had temporarily barred Sun Pharma from launching Leqselvi in the United States due to an ongoing legal battle with Incyte Corporation. The appellate court's decision, which came shortly ...

On Thursday, April 10, Sun Pharma announced that the U.S. Court of Appeals for the Federal Circuit has vacated a preliminary ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...